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Background
To maximize safety, women in HIV vaccine trials should
avoid pregnancy, but pregnancy often occurs. We evalu-
ated baseline risk factors for pregnancy in this trial.
Methods
Women who were unsterilized, non-pregnant, and agreed
to avoid pregnancy for at least 1-month after her final vac-
cination (''vaccination period'') were analyzed. Each
woman's vaccination period was calculated based on her
final vaccination, regardless of whether she completed all
three vaccinations (trial unexpectedly halted). At two of
five sites, hormonal contraception was required and pro-
vided for free. We calculated pregnancy rates overall and
by vaccination period, and used Cox regression to exam-
ine baseline contraceptive availability, partner, and per-
sonal variables for associations with pregnancy.
Results
Of the 352 women (mean age 23.9 yrs; 98.9% black) in
the six months prior to enrollment, 83.2% had a main
partner, 48.9% had partners of unknown HIV-status,
83.8% had vaginal sex only; 6.2% anal sex; 9.9% oral sex,
and 58.5% and 57.1% reported injectable contraception
and consistent condom use, respectively. At this writing
17 4.8%(17/352) pregnancies occurred; updated analysis
forthcoming. The pregnancy rate was 0.53/100-women-
months (0.33–0.85) and did not differ by vaccination
period, site, nor by use of condoms or hormonal meth-
ods. In multivariable analysis, having a partner of
unknown HIV-status was inversely associated with preg-
nancy Hazard Ratio(95%CI) 0.2(0.1–0.8), and was posi-
tively associated with engaging in oral sex 2.9(1.0–8.5)
and marijuana use 3.3(0.7–14.9). Associations with oral
sex were not mediated by condom use; null associations
with contraception may be explained by non-adherence
and misclassification.
Conclusion
Pregnancy was not reduced during the vaccination period,
despite women's professed commitment to avoid such
pregnancies. Pregnancy depended on a specific high-risk
participant profile and HIV-status disclosure within sexual
partnerships. More discerning methods for determining
pregnancy intent and understanding partnership dynam-
ics are needed to minimize pregnancies in South African
trials.
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